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(2 of 2 MGUS cultures tested), and did not correlate with the capacity t o respond t o IL-6 stimulation (n = 17, P > .05) or a detectable level of endogenous IL-6 fn = 15, P > .05).
Additional studies were performed with PCD cell lines t o characterize the interrelationship of CD40 activation and IL-6 production. Fifty percent t o greater than 95% of cells from the RPM1 8226 and ARH77 lines expressed CD40, whereas 6% of U266 cells were CD40f. For RPM1 8226, ARH-77, and U266 cells, the increased MCC formation after anti-CD40 stimulation was not affected by the presence of an anti-IL-6 neutralizing MoAb and was not accompanied by detectable IL-6 secretion. There was no apparent increase in IL-6 mRNA transcription following G28-5 treatment of U266 or RPM1 8226 cells. Our observations indicate that CD40 is expressed in a subset of human myeloma cells present in various PCDs. Cell-line studies suggest that the CD40' myeloma cell may regulate MM clonogenic colony formation without activating the IL-6 pathway. human B cells and a murine lymphoma line transfected with the human CD40 gene.15 Conversely, binding of 1L-6 to the high affinity IL-6R (which is distinct from CD40) results in increased phosphorylation of CD40, which in turn stimulates IL-6 prod~ction.'~ This apparent interconnected signaling between IL-6 and CD40 led to the hypothesis of a "CD40/ IL-6 loop", by which CD40 functions to receive and regulate IL-6-dependent signals in B cells."
At present, it is unclear whether CD40 plays a similar antiapoptotic role for malignant B cells or influences their autocrine IL -6 This issue is clinically relevant in MM, in view of the observations that MM disease progression may be affected by autocrine or paracrine action of IL-6.I6 An elevated IL-6 serum level was correlated with MM disease ~everity,'"'~ and treatment with an anti-IL-6 MoAb produced a short-term remission in one plasma cell leukemia (PCL) patient.z" This study characterizes the distribution of CD40 in bone marrow (BM) samples from various PCD patients to explore the role of CD40 activation in IL-6-related growth modulation of MM. The relationship between CD40 activation and IL-6 production also was examined with MM cell lines for the purpose of characterizing activity of the CD40AL-6 loop.
marrow aspirates of patients with monoclonal gammopathy of undetermined significance (MGUS) (n = 12), Waldenstrom's macroglobulinemia (WM) (n = 3), and primary amyloidosis (AL) (n = 5). Peripheral blood mononuclear cells with extensive myeloma involvement from 2 PCL patients also were used for MM clonogenic colony (MCC) assays. Diagnosis and classification of PCD were based on the criteria of clinical presentation, M-protein level in serum andor urine, presence or absence of lytic bone lesions, and histopathologic distribution of BM plasma cells."~'' BM aspirates were obtained during routine procedures for diagnosis or treatment. All BM samples were procured according to a protocol approved by the Institutional Review Board for Human Protection, Baylor University Medical Center.
Immunoperoxidase staining protocol. (328-5 reactivity with PCD patient BM biopsies was determined by the immunoperoxidase technique as described previously.23 Briefly, Zenker formalin-fixed, paraffin-embedded BM biopsy sections were deparaffinized overnight, rehydrated, and treated with Lugol's iodine and 5% sodium thiosulfate. The sections were washed in distilled water, then treated with 1% HzOz in absolute methanol and normal horse serum. Immunoperoxidase staining involved 60-minute incubations at room temperature with the primary antibody, then secondary antibody (biotinylated horse anti-mouse IgG), followed by the enzyme avidin biotin-conjugated horseradish peroxidase (Vectastin ABC Elite kit; Vector Laboratories, Burlingame, CA) and substrate (0.02% 3-amino-9-ethylcarbazole: 0.03% HzOz: 5% N,N-dimethylformamide). The sections were counterstained with Meyer's hematoxylin. Reactivity was determined by light microscopy, in comparison with a section treated with the negative control MOPC21 mouse Ig. Plasmacytoid cells in each biopsy section were identified based on histopathologic features by an independent pathologist. Reactivity of (328-5 with plasmacytoid cells was confirmed by concomitant determinations with the myeloma cell-reactive MoAb MM4.23 CD40 reactivity with each biopsy was graded as -: <5% reactive plasmacytoid cells; +: 5% to 25% reactive plasmacytoid cells; ++: 26% to 50% reactive plasmacytoid cells; + + +: >50% reactive plasmacytoid cells.
MCC-forming assay. MCC-forming assay of MM cell lines was performed as previously de~cribed.'~ The number of clonogenic units in treated and untreated cultures was determined with a limiting dilution assay, using Spearman's estimate. For culture of patient MCC, BM mononuclear cells were obtained by hypaque ficoll centrifugation (400g for 20 minutes) and resuspended in Iscove's Modified Dulbecco Media (IMDM) at 4 X 106/mL. MCC cultures for PCL patients were established with hypaque-ficoll interphased peripheral blood mononuclear cells. One hundred-microliter aliquots of cells were dispensed to individual wells of a 24-well culture plate containing methylcellulose (40% vol/vol) in 20% fetal calf serum (FCS) and IMDM. Other culture conditions were tested, including variations of the double-layered agarose technique or the use of various culture s~p p l e m e n t s . '~~~~ These conditions did not substantially improve the generation or yield of MCCs. Cells were incubated with or without IL-6 (0.5 to 5 ng/mL) and/or (328-5 (0.375 to 3.75 pg/ mL). Optimal concentrations of these reagents were established in cell line studies with U266 and RPMI 8226 cells. Tenfold increases in (328-5 or IL-6 concentrations did not significantly vary the level of stimulation for either cell lines (data not shown). The number of MCCs (>50 cells per colony) was counted by inverted microscopy at days 10 to 14. Determinations of the mean number of MCCs with or without added IL-6 or G28-5 were based on triplicate determinations, with intrareplicate variations of 0% to 15%. An increase of 35% or greater in the mean number of MCCs was arbitrarily considered as a significant response. The role of IL-6 in MCC stimulation was determined by coincubation with a blocking concentration (7.5 pg/mL) of an anti-human IL-6 neutralizing MoAb (R & D Systems, Minneapolis, MN).
Flow cytometric analysis. Surface antigen expression of MM cells was determined by single color or dual color flow cytometric immunofluorescence as described p r e v i o~s l y .~~ Briefly, myeloma cells were harvested at logarithmic growth, washed twice, and resuspended at 2 X 107/mL in phosphate buffered saline (PBS). Incubation (4°C for 30 minutes) was carried out with (328-5, followed by a fluorescein-conjugated goat anti-mouse Ig antibody (FITC-GaMIg; from Tag0 . The threshold of detection ( 2 3 pg/mL) is within the same order of magnitude as proliferative assays with IL-6-dependent cell lines (-2 ~g/mL).'~ All normal subjects tested had less than the detectable level of IL-6 ( 2 3 pg/mL) in BM (n = 15). MCC culture media and FCS were prescreened and did not contain a detectable level of IL-6. The IL-6 level of MCC cultures following (328-5 incubation could not be determined because of the requirement of methylcellulose in MCC culture media.
Reversetranscriptionpolymerasechainreaction(RT-PCR).
Semiquantitative determination of cellular IL-6 mRNA was canied out by the PCR reaction, using MM cell cDNA synthesized by RT. MM cells were cultured with or without (328-5 for 48 hours. Our earlier 3H-thymidine uptake studies showed an increased proliferation by (328-5 in the same culture p e r i~d .~ Cellular RNA was extracted from equal numbers of cells by the guanidine isothiocyanate/acid phenolchloroform method?' Total RNA was annealed to an IL-6 specific 3' primer and reverse transcribed with M-MLV reverse transcriptase
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From (GeneAmp RNA PCR kit; Perkin Elmer Cetus, Norwalk, CT). The reverse-transcription products and PCR reagents were kept at the primer-annealing temperature before mixing and addition of the 5' (23mer) and 3' (22mer) oligodeoxynucleotide primers that flank nucleotides 57-639 of the mature IL-6 message (Human IL-6 Amplimer Set; Clontech Lab, Palo Alto, CA). Amplification was camed out with Taq polymerase and a Perkin Elmer-Cetus Thermocycler (denaturing: 94"C, 1 minute; annealing: 5.5" or 6 0 T , 45 seconds; elongation: 7 2 T , 45 seconds; 35 cycles). Amplified DNA of the expected size (628 bp) was identified following agarose (1 S % ) electrophoresis and ethidium bromide staining, Internal standards included concomitant RT and amplification of mRNA for the heat shock cognate protein HSC70, a constitutively expressed molecular chaperone,'" and p-actin mRNA. Equivalent levels of amplified HSC70 cDNA or p-actin cDNA in treated and untreated samples indicated that the source of amplified IL-6 cDNA from G28-5-treated and untreated samples was derived from equivalent amounts of total cellular RNA. The use of equal amounts and quality of total RNA could be further shown by gel electrophoresis of the RNA samples.
RESULTS
CD40 expression in PCD BM biopsies.
Previous studies have carried out limited determinations of CD40 expression in MM and PCL BM.'" In this study, we examined CD40 expression in 28 patient BM biopsies from MM, PCL, as well as other PCDs, using the MoAb G28-5 and the immunoperoxidase technique. Clinical diagnosis, the frequency distribution of plasma cells and their isotype of each case are shown in Table 1 . Twenty-one of the 28 PCD cases tested contained 2 5 % of G28-S-reactive plasmacytoid cells (Table  1) . CD40 was expressed in >25% (++) of plasmacytoid cells in 6 of 14 MM cases, 2 of 2 PCL cases, 1 of 2 cases of WM, and 1 of 7 cases of MGUS tested. One of 2 cases of AL amyloid had low CD40 expression (Table 1) . No G28-5 reactivity was evident with BM granulocytic and erythroid components. These observations indicate that CD40 was expressed on plasma cells from various PCDs.
Effect of anti-CD40 MoAb binding on MCC formation. In vitro MCC forming cells may be closely related to the MC stem cells in
The pathophysiologic role of CD40 activation in human MM cell growth was explored by examining the effect of G28-5 incubation on MCC formation of PCD patient primary BM cultures. MCCs were identified by their colony morphology, which is distinct from normal BM-CFUs, and by identification of cells with plasmacytoid features following Wright-Giemsa staining.?," The plasmacytic nature of MCCs was confirmed by their expression of the relevant cytoplasmic monoclonal light chain as determined by immunohistology and confirmation of Ig-heavy chain utilization by PCR with culture-harvested MCCs (n = 7).
Seventeen of 24 PCD BM specimens tested cocomitantly for CD40 expression and MCC formation had a positive MCC culture, including 15 of 22 cases of primary BM cultures and 2 of 2 PCL peripheral blood cultures (Table 2) . With intrareplicate variations that ranged from 0% to 15% (triplicate determinations), a 235% increase in the mean number of MCC was arbitrarily considered as a significant response. Eleven of the 17 (65%) MCC+-cultures had a 235% increase in myeloma MCCs following treatment with (328-5 (Table 2) . Responders included BM specimens from Regression analyses indicated that the frequency of CD40' myeloma cells was correlated with the percentage of plasmacytosis in BM specimens examined (Fig lA, P = Abbreviation: NT, not tested. 6 neutralizing MoAb added at day 0. r = .4, n = 28). However, the magnitude of increase in MCC following anti-CD40 stimulation of MCC' cultures was not proportional to the frequency of CD40+ myeloma cells (Fig lB, P > .05, r = .2, n = 17) or disease status. BM biopsies from 7 PCD patients that did not produce MCCs were examined retrospectively for CD40 expression. Six of these patients (DS, JB, RW, EW, IJ, HW) expressed CD40, with 3 of the 6 specimens (DS, EW, HW) containing 225% CD40+ myeloma cells (data not shown). These observations suggest that CD40 expression may not be the limiting determinant of MM clonogenic potential in vitro, and that only a subset of CD40' MM cells may be involved in MCC formation.
Role of IL-6 in MCC stimulation. The effect of IL-6 on 3029 MCC formation was compared with that of (328-5 to explore the relationship between IL-6 and anti-CD40 MoAb-mediated MCC stimulation. MCC formation did not appear to depend on the presence of endogenous IL-6 ( P > .05), which was detected in 7 of 21 uncultured BM and peripheral blood specimens (MM, 2 of 6 cases; WM, 0 of 2 cases; PCL, 2 of 2 cases; MGUS, 3 of 8 cases; Table 2 ).
Exogenous IL-6-enhanced MCC formation ( 2 3 5 % ) in 5 of 17 BM and peripheral blood primary cultures tested (2 of 5 MM, 2 of 2 PCL, and 1 of 6 MGUS; Table 2 ). All 5 IL-6-responsive cultures also responded to (328-5 stimulation. However, responsiveness to anti-CD40 MoAb stimulation of MCC' cultures did not correlate with IL-6 responsiveness (P = .07, Fisher's exact test, n = 17) or a detectable IL-6 level ( P > S , Fisher's exact test, n = 15).
In two MGUS primary BM cultures tested so far, cotreatment with a neutralizing anti-IL-6 MoAb abrogated the IL-6-enhanced MCC response (patient CB) but did not affect the stimulatory effect of (328-5 (CB and HL, Table 2 ). Our observations suggest that anti-CD40 stimulation of MCC formation may not require an active IL-6 pathway.
G28-5 and IL-6 stimulation of human MM cell lines. Established PCD cell lines were used to better define the interrelationship of MCC activation by (328-5 and IL-6 binding. Five of five PCD cell lines tested contained CD40' myeloma cells (Table 3 ). The CD40+ subset coexpressed CD10, CD19, CD38, CD56, and sIg (Table 3 ). The low number of CD40' U266 cells also coexpressed the IL-6R. By comparison, 50% or greater of RPMI 8226, ARH-77, and GM13 12 myeloma cells expressed CD40, of which only a minority expressed the IL-6R (Table 3) .
We examined the effect of (328-5 and IL-6 binding on MCC formation of RPMI 8226 and ARH-77 cell lines, with U266 cells serving as reciprocal negative control (Table 4) . Both RPMI 8226 and ARH-77 cells had a doubling of MCCs (102% and 128% increase, respectively; P < .05) following G28-5 treatment, which affected U266 MCC formation only moderately (22%; P < .05; Table 4 ). By comparison, IL-6 did not significantly increase MCC formation of RPMI 8226 or ARH-77 cells ( P > .OS), whereas the level of IL-6-stimulated U266 MCCs was 2.4-fold that of unstimulated cultures (139%, P < .001) ( Table 4) .
Coincubation with an anti-IL-6 MoAb did not affect the baseline level of U266 MCC formation, but was effective in eliminating 75% of the increased MCC response by IL-6 (Table 4) . By comparison, anti-IL-6 MoAb treatment did not significantly alter the G28-5-stimulated MCC level in U266, RPMI 8226, and ARH-77 cultures (Table 4 ). These observations suggest that MCC stimulation by G28-5 was independent of secretable IL-6.
Characterization of IL-6 secretion and IL-6 mRNA. To define the activity of the CD40/IL-6 loop, we examined cell culture IL-6 levels with the high responders RPMI 8226, ARH-77 and low responder U266 cells. Cells were cultured for 48 hours, which we found previously to be appropriate for generating an enhanced 3H-thymidine uptake response by C128-5.~ The IL-6 level in culture supernatants of all three cell lines was below the threshold of detection ( 2 3 pg/mL) before and after incubation with (328-5 (data not shown). (Fig 2, lane  4) . There was no apparent increase in the level of IL-6 amplification product from RNA of U266 cells that were cultured in presence of G28-5 (lane 5). These findings suggest that anti-CD40 stimulation of MCC was not accompanied by an increased IL-6 transcription.
DISCUSSION
Our study showed that CD40 was expressed on human myeloma cells in BM of patients with various PCDs. Previ- ous determinations of CD40 expression in PCD were restricted to limited numbers of PCL and MM cases. Hamilton et ai4 showed that CD40 was expressed on approximately 40% of myeloma cells in 1 of 2 PCL patients tested, whereas 2 of 2 myeloma cases did not contain CD40' myeloma cells. Jackson et a15 described weak to moderate cytoplasmic staining of CD40 in myeloma plasma cells of 4 of 7 patients. Two of 16 patient samples showed weak surface membrane expression.' By comparison, the recent studies by Westendorf et al' and Bakkus et al' showed CD40 expression on myeloma cells from 7 of 7 and 10 of 10 MM specimens, respectively. Our study showed that 75% of the 28 cases of PCD BM tested contained CD40' myeloma cells, based on immunohistochemical analysis. G28-5 reactivity with patients having MGUS, as well as AL-amyloidosis, WM, MM, and PCL indicates that the CD40' myeloma cell is present in asymptomatic as well as overtly malignant PCDs. With the exception of the 2 cases of AL-amyloidosis BM tested, each of other PCD clinical subsets encompassed specimens with a high frequency of CD40' myeloma cells. Heterogeneity of CD40 expression was evident within individual myeloma cell populations. (328-5 reactivity ranged from 5% to greater than 90% of total plasmacytoid cells in BM specimens tested. This heterogeneity was also manifested in a difference in CD40 antigenic density on individ- For Our ohservation of an enhanced MCC response following G28-5 treatment indicates that the CD40 pathway is functionally active in patient myeloma cells. For normal resting B cells, interaction of CD40 with its natural T-cell ligand Gp39'.'* provides a second signal for normal resting B cells that leads to polyclonal B-cell activation' and heavy chain switching.''.'* It is presently unclear whether CD40 serves a similar antiapoptotic role for cell activation in hematologic malignancies. Uckun et alx showed that CD40 is expressed on the clonogenic subset of human B lymphocytic leukemias and lymphomas. Various reports indicated that CD40 stimulation by its MoAb or a synthetic ligand may stimulate,"." inhibit,"' or had no effect"' on human B-cell lymphoma cell growth. The generation of an optimal growth-inhibitory signal on human lymphoma cell lines required the artificial MoAb cross-linking before the binding of CD40.'" By contrast, soluble anti-CD40 MoAb and IL-4-stimulated the proliferation of tumor cells isolated from follicular lymphoma patients? Similar conditions also promoted 'H-thymidine uptake of leukemia cell clones derived from S of 7 B-chronic lymphocytic leukemia patients, but poorly stimulated their differentiation into Ig-secreting ceIk3' An enhanced 'H-thymidine uptake following CD40 binding alone has been previously described by us and others with the RPMI 8226 line' and the IL-6-dependent myeloma line ANBL-6." In this study, approximately 65% of CD40' PCD BM cultures had increased MCC formation following (328-5 binding. This assessment may represent an underestimation of CD40 responsiveness because variations in the MCC assay limit the definition of a positive response to increases of 35% or higher. The 1 I G28-5-responsive cases were comprised of specimens from MM, PCL, as well as MGUS, WM, and AL amyloidosis patients. These findings provide indirect evidence that the clonogenic subset of monoclonal plasma cells expresses CD40, which may remain active in pathways that regulate myeloma cell proliferation and MCC formation in benign as well as malignant forms of PCD. The limited number of cases analyzed precludes definitive comparisons on the relative frequency of CD40-responsiveness in each PCD clinical subset.
According to Clark and Shu," CD40 may function to receive and regulate IL-6-dependent activation signals in B cells (the CD40/IL-6 loop). The CD40/IL-6 loop does not appear to be the predominant mechanism of CD40-mediated MCC stimulation in patient primary BM cultures. Only 7 of 15 MCC' patients primary BM cultures had detectable IL-6 before culture, indicating that MCC formation was not dependent on the presence of IL-6. Furthermore, responsiveness to (328-5 stimulation was not correlated with IL-6 responsiveness nor with a preexisting detectable level of IL-6. Coincubation with a neutralizing anti-IL-6 MoAb also did not affect the anti-CD40 stimulated MCC response in two MGUS patient primary BM cultures tested. These observations suggest that enhancement of MCC formation via the IL-6R and CD40 may use distinct activation pathways. Additional evaluations with MM cell lines support this premise. For RPM1 8226 and ARH-77 cells, the doubling of MCCs by G28-5 did not produce detectable levels of the IL-6 protein. There was no detectable IL-6 transcription in unstimulated and (328-S-stimulated RPMI 8226 ccll cultures. For U266 cells that actively transcribed IL-6, there was no apparent increase in IL-6 mRNA level in G28-Sstimulated cultures. These observations argue against the possibility that 1L-6 may be produced as a consequence of anti-CD40 MoAb binding and used autocritically without secretion." Finally, cotreatment with an anti-lL-6 MoAb, which eliminated the majority of the MCC-enhancing effect For personal use only. on October 3, 2017. by guest www.bloodjournal.org From of exogenous IL-6 on U266 cells, was ineffective in altering the MCC stimulatory response of G28-5 for RPMI 8226, ARH-77, or U266 cells.
Our findings differed from those with the IL-6-dependent MM line ANBL-6, which responded to CD40 activation with an enhanced growth pattern and increased IL-6 mRNA production and cytokine secretion.h Unlike ARH-77, RPMI 8226, and U266 cells, whose growth is independent of exogenous IL-6, the anti-CD40 growth stimulatory effect on ANBL-6 was partially blocked by an anti-IL-6 MoAb. This difference may reflect use of distinct CD40 signaling pathways, as IL-6-growth-dependent myeloma cells also differed from their IL-6-nonresponding counterparts in terms of receptor expression, cytokine secretion, and disease aggressiveness.'7,34 For IL-6-dependent hybridoma cells, IL-6 gene expression and signaling involves a common pathway with tyrosine phosphorylation of a 160-!dl protein (p160) and activation of a protein kinase that is distinct from phosphokinase C and phosphokinase A. This pathway appears to be independent of phosphotidyl inositol turnover and Ca++ ion in flu^.'^,'^ By comparison, signaling via CD40 in normal B cells results in tyrosine phosphorylation that depends on phosphotidyl inositol and Ca++ turno~er."~'~ Further evaluations of these activation pathways will be useful in characterizing the interplay of IL-6R and CD40 in IL-6-growth-dependent and independent MM.
Multivariate analysis of CD40 expression and MCC responsiveness suggests that variables in addition to CD40 expression may be involved in CD40-mediated MCC formation and/or its regulation: CD40+ myeloma cells were detected in both MCC+ and MCC-patient primary BM cultures, and the magnitude of MCC stimulation by G28-5 did not correspond to the frequency of CD40' myeloma cells before culture. Our findings of heterogeneity of the CD40 myeloma cell with respect to phenotype and CD40 antigenic density suggest that MCC formation and its regulation may engender a finite subset of these CD40' myeloma cells. Additional factors may also contribute towards an optimal MCC response, such as cytokines other than IL-6 that may serve an autocritic or paracritic role in promoting malignant Bcell or myeloma-cell g r~w t h . ' '~~'~~~ Further studies in these areas may help define the pathophysiologic role of CD40 in the growth maintenance and disease progression of patients with various PCDs.
